Seasonal and pandemic flu will be focus of the project.

Eden Biodesign will provide ImmunoBiology with a range of development and manufacturing services for its vaccine program that targets both seasonal and pandemic flu.

“Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a clinical trial application and is consistent with our aggressive timelines for bringing our viral lead product to the clinic,” says Graham Clarke, CEO of ImmunoBiology. 

Eden Biodesign is the operator of the National Biomanufacturing Center (NBC) facility.

Previous articleRanbaxy Gets Ready to Penetrate Ambien’s $2B Market
Next articleSigma-Tau Leads Triumvirate Investigating New Malaria Treatment